TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Negative Pressure Wound Therapy in High Risk Patients Undergoing Cesarean
Brief Summary: The investigators propose a prospective, randomized trial evaluating the use of negative pressure wound therapy (NPWT) with high risk obstetrical patients. The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients. The investigators aim to look at all wound complications such as infection and disruption and will be using Prevena incision management system for our NPWT device .


Options:
A: Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: Negative pressure wound therapy | Arm Label: Standard dressing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Negative pressure wound therapy; Assigned to Arm(s): Negative Pressure Wound Therapy
B: Arm Label: Closed Incision Wound vacuum (Prevena); Type: EXPERIMENTAL; Interventions: Device: Closed incision wound vacuum (Prevena) | Arm Label: Routine Wound Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Closed incision wound vacuum (Prevena); Assigned to Arm(s): Closed Incision Wound vacuum (Prevena)
C: Arm Label: Prevena device (Group A); Type: EXPERIMENTAL; Interventions: Device: Prevena device (Group A) | Arm Label: Conventional dressing (Group B); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Prevena device (Group A); Assigned to Arm(s): Prevena device (Group A)
D: Arm Label: Vacuum assisted closure; Type: EXPERIMENTAL; Interventions: Procedure: vacuum assisted closure | Arm Label: Axillary dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Axillary dissection | Intervention Type: PROCEDURE; Name: vacuum assisted closure; Assigned to Arm(s): Vacuum assisted closure | Intervention Type: PROCEDURE; Name: Axillary dissection; Assigned to Arm(s): Axillary dissection

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Negative Pressure Wound Therapy in High Risk Patients Undergoing Cesarean
Brief Summary: The investigators propose a prospective, randomized trial evaluating the use of negative pressure wound therapy (NPWT) with high risk obstetrical patients. The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients. The investigators aim to look at all wound complications such as infection and disruption and will be using Prevena incision management system for our NPWT device .


Options:
A: Arm Label: Current Standard; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing | Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: Prevena (Negative Pressure Wound Therapy Device) | Intervention Type: DEVICE; Name: Prevena (Negative Pressure Wound Therapy Device); Assigned to Arm(s): Negative Pressure Wound Therapy | Intervention Type: DEVICE; Name: Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing; Assigned to Arm(s): Current Standard
B: Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: Negative pressure wound therapy | Arm Label: Standard dressing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Negative pressure wound therapy; Assigned to Arm(s): Negative Pressure Wound Therapy
C: Arm Label: High Risk - Prevena Care; Type: EXPERIMENTAL; Interventions: Device: Prevena Care | Arm Label: High Risk - Dry Gauze Dressing Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Dry gauze dressing care | Arm Label: Low Risk - Dry Gauze Dressing Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Dry gauze dressing care | Intervention Type: DEVICE; Name: Prevena Care; Assigned to Arm(s): High Risk - Prevena Care | Intervention Type: DEVICE; Name: Dry gauze dressing care; Assigned to Arm(s): High Risk - Dry Gauze Dressing Care, Low Risk - Dry Gauze Dressing Care
D: Arm Label: Prevena device (Group A); Type: EXPERIMENTAL; Interventions: Device: Prevena device (Group A) | Arm Label: Conventional dressing (Group B); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Prevena device (Group A); Assigned to Arm(s): Prevena device (Group A)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Negative Pressure Wound Therapy in High Risk Patients Undergoing Cesarean
Brief Summary: The investigators propose a prospective, randomized trial evaluating the use of negative pressure wound therapy (NPWT) with high risk obstetrical patients. The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients. The investigators aim to look at all wound complications such as infection and disruption and will be using Prevena incision management system for our NPWT device .


Options:
A: Arm Label: Current Standard; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing | Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: Prevena (Negative Pressure Wound Therapy Device) | Intervention Type: DEVICE; Name: Prevena (Negative Pressure Wound Therapy Device); Assigned to Arm(s): Negative Pressure Wound Therapy | Intervention Type: DEVICE; Name: Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing; Assigned to Arm(s): Current Standard
B: Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: Negative pressure wound therapy | Arm Label: Standard dressing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Negative pressure wound therapy; Assigned to Arm(s): Negative Pressure Wound Therapy
C: Arm Label: Dry Dressing; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: V.A.C. by K.C.I. | Intervention Type: DEVICE; Name: V.A.C. by K.C.I.; Assigned to Arm(s): Negative Pressure Wound Therapy
D: Arm Label: Standard wound dressing OPEN; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PICO dressing OPEN; Type: EXPERIMENTAL; Interventions: Device: Negative pressure wound therapy with PICO (Smith & Nephew) | Arm Label: Standard dressing EVAR; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PICO dressing EVAR; Type: EXPERIMENTAL; Interventions: Device: Negative pressure wound therapy with PICO (Smith & Nephew) | Intervention Type: DEVICE; Name: Negative pressure wound therapy with PICO (Smith & Nephew); Assigned to Arm(s): PICO dressing EVAR, PICO dressing OPEN

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Self-Management Group-Intervention on Participation in Post-Stroke Patients.
Brief Summary: Stroke is defined as a sudden vascular accident that causes brain damage and neurological impairment. Literature shows that a stroke has a negative effect on participation. Self-Management (SM) is defined as health promotion and education programs used mostly for people with chronic diseases, which aim at helping patients to maintain a feeling of wellness. The primary aim of this study is to assess the effectiveness of a group-based SM program for post-stroke patients in a community setting, and its contribution to improving participation, compared to standard care.


Options:
A: Arm Label: Robotic Treatment plus VR; Type: EXPERIMENTAL; Interventions: Device: Robotic Treatment plus VR | Arm Label: Robotic treatment without VR; Type: ACTIVE_COMPARATOR; Interventions: Device: Robotic Treatment plus VR | Arm Label: Conventional treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Robotic Treatment plus VR | Intervention Type: DEVICE; Name: Robotic Treatment plus VR; Assigned to Arm(s): Conventional treatment, Robotic Treatment plus VR, Robotic treatment without VR
B: Arm Label: Self-Management group-intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Self-Management group-intervention | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Care | Intervention Type: BEHAVIORAL; Name: Self-Management group-intervention; Assigned to Arm(s): Self-Management group-intervention | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard Care
C: Arm Label: Virtual Reality; Type: EXPERIMENTAL; Interventions: Procedure: Virtual Reality | Arm Label: Paper and Pencil; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Paper and Pencil | Arm Label: Conventional Therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Therapy | Intervention Type: PROCEDURE; Name: Virtual Reality; Assigned to Arm(s): Virtual Reality | Intervention Type: PROCEDURE; Name: Paper and Pencil; Assigned to Arm(s): Paper and Pencil | Intervention Type: PROCEDURE; Name: Conventional Therapy; Assigned to Arm(s): Conventional Therapy
D: Arm Label: sequential training group (SEQ); Type: EXPERIMENTAL; Interventions: Behavioral: aerobic exercise training, Behavioral: cognitive training | Arm Label: control intervention group (CI); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: control training | Intervention Type: BEHAVIORAL; Name: aerobic exercise training; Assigned to Arm(s): sequential training group (SEQ) | Intervention Type: BEHAVIORAL; Name: control training; Assigned to Arm(s): control intervention group (CI) | Intervention Type: BEHAVIORAL; Name: cognitive training; Assigned to Arm(s): sequential training group (SEQ)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy in South Korea and Taiwan
Brief Summary: Primary Objective:

To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable maximally tolerated daily statin therapy with or without other lipid-modifying therapy (LMT) in comparison with placebo after 24 weeks of treatment in high cardiovascular risk participants with hypercholesterolemia in South Korea and Taiwan.

Secondary Objectives:

* To evaluate the effect of alirocumab in comparison with placebo on LDL-C after 12 weeks of treatment.
* To evaluate the effect of alirocumab on other lipid parameters: apolipoprotein B (Apo B), non high-density lipoprotein cholesterol (non-HDL-C), total cholesterol (TC), lipoprotein (a) (Lp \[a\]), high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs), and apolipoprotein A-1 (Apo A-1).
* To evaluate the safety and tolerability of alirocumab.
* To evaluate the development of anti-alirocumab antibodies (ADA).


Options:
A: Arm Label: Alirocumab therapy group; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab | Arm Label: standard statin therapy group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab therapy group
B: Arm Label: Bococizumab (PF-04950615;RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615;RN316) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Bococizumab (PF-04950615;RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Alirocumab), Drug: Lipid-Modifying Therapy (LMT) | Arm Label: Alirocumab 75 mg Q2W/Up to 150 mg Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Placebo (for Alirocumab); Assigned to Arm(s): Placebo Q2W | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W, Placebo Q2W
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Evolocumab; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Determination of the Role of Oxygen on Mechanisms Involved in Ischemia-reperfusion Injury in Suspected Acute Myocardial Infarction by Biomarkers. A Sub Study to the DETO2X-AMI Trial.
Brief Summary: Oxygen treatment is widely used in acutely ill patients, both pre-hospital and in hospital. The indication for oxygen is sometimes unquestionable, such as in many hypoxic patients, but in other situations its use is more of a practise and much less based on scientific evidence. In particular, oxygen treatment is routinely used in patients with a suspected heart attack and variably recommended in guidelines, despite very limited data supporting a beneficial effect. Indeed, a few studies even indicate that oxygen treatment might be harmful.

Immediate re-opening of the acutely blocked artery to the heart muscle is the treatment of choice to limit permanent injury. However, the sudden re-initiation of blood flow achieved with primary percutaneous coronary intervention (PCI), the reopening and stenting of the blocked vessel, can give rise to further endothelial and myocardial damage, so-called reperfusion injury. Ischemia and reperfusion associated myocardial injury (IR-injury) involves a wide range of pathological processes. Vascular leakage, activation of cell death programs, thrombocytes and white blood cells leading to extended inflammation and formation of clots are examples of those effects.

The role of oxygen treatment on these pathological processes, on the extent of IR-injury and the final infarct size in patients with acute myocardial infarctions (AMI) has not previously been studied.

In an ongoing national multicentre, randomized, registry based clinical trial, the DETO2X-AMI trial (NCT01787110), the effect of oxygen on morbidity and mortality in ACS patients is being investigated.

The present DETO2X-biomarkers study is a substudy of the DETO2X-AMI trial, evaluating the effect of oxygen treatment on biological systems involved in the pathogenesis of reversible and irreversible myocardial damage and cell death in ACS.


Options:
A: Arm Label: Telemonitoring (Medly); Type: EXPERIMENTAL; Interventions: Device: Medly | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Medly; Assigned to Arm(s): Telemonitoring (Medly)
B: Arm Label: iVAPS with AutoEPAP; Type: EXPERIMENTAL; Interventions: Device: Astral | Arm Label: iVAPS with manual EPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Astral | Intervention Type: DEVICE; Name: Astral; Assigned to Arm(s): iVAPS with AutoEPAP, iVAPS with manual EPAP
C: Arm Label: Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Oxygen | Arm Label: No oxygen; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): Oxygen
D: Arm Label: Observational; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interventional; Type: EXPERIMENTAL; Interventions: Device: CHROMED monitoring system | Intervention Type: DEVICE; Name: CHROMED monitoring system; Assigned to Arm(s): Interventional

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilipino Americans Go4Health Weight Loss Program to Prevent Heart Disease
Brief Summary: This is a pilot randomized controlled trial intervention to improve lifestyle behaviors (physical activity and health diet) for Filipino Americans with type 2 diabetes on metformin. If the PilAm Go4Health intervention demonstrates potential efficacy, it may identify effective intervention strategies to significantly reduce risks for heart disease risks (i.e., metabolic syndrome) in Filipino Americans.


Options:
A: Arm Label: Diet + Water; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counseling | Arm Label: Diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary counseling | Intervention Type: BEHAVIORAL; Name: Dietary counseling; Assigned to Arm(s): Diet, Diet + Water
B: Arm Label: Sugar-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Sugar-sweetened soft drink | Arm Label: Aspartame-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Aspartame-sweetened soft drink | Arm Label: Semi-skimmed milk; Type: ACTIVE_COMPARATOR; Interventions: Other: Semi-skimmed milk | Arm Label: Water; Type: PLACEBO_COMPARATOR; Interventions: Other: Water | Intervention Type: OTHER; Name: Sugar-sweetened soft drink; Assigned to Arm(s): Sugar-sweetened soft drink | Intervention Type: OTHER; Name: Aspartame-sweetened soft drink; Assigned to Arm(s): Aspartame-sweetened soft drink | Intervention Type: OTHER; Name: Semi-skimmed milk; Assigned to Arm(s): Semi-skimmed milk | Intervention Type: OTHER; Name: Water; Assigned to Arm(s): Water
C: Arm Label: Sugar-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Sugar-sweetened soft drink | Arm Label: Aspartame-sweetened soft drink; Type: EXPERIMENTAL; Interventions: Other: Aspartame-sweetened soft drink | Arm Label: Semi-skimmed milk; Type: ACTIVE_COMPARATOR; Interventions: Other: Semi-skimmed milk | Arm Label: Water; Type: PLACEBO_COMPARATOR; Interventions: Other: Water | Intervention Type: OTHER; Name: Sugar-sweetened soft drink; Assigned to Arm(s): Sugar-sweetened soft drink | Intervention Type: OTHER; Name: Aspartame-sweetened soft drink; Assigned to Arm(s): Aspartame-sweetened soft drink | Intervention Type: OTHER; Name: Semi-skimmed milk; Assigned to Arm(s): Semi-skimmed milk | Intervention Type: OTHER; Name: Water; Assigned to Arm(s): Water
D: Arm Label: Intervention - PilAm Go4Health Program; Type: EXPERIMENTAL; Interventions: Behavioral: PilAm Go4Health Weight-loss Program | Arm Label: Active control - pedometer only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Control | Intervention Type: BEHAVIORAL; Name: PilAm Go4Health Weight-loss Program; Assigned to Arm(s): Intervention - PilAm Go4Health Program | Intervention Type: BEHAVIORAL; Name: Active Control; Assigned to Arm(s): Active control - pedometer only

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SheppheartCABG. A Randomised Clinical Trial of a Comprehensive Physical and Psycho-educative Rehabilitation Programme Plus Usual Care Versus Usual Care in Phase 1 Rehabilitation After Coronary Artery Bypass Grafting
Brief Summary: Background: Patients undergoing coronary artery bypass graft surgery often experience a range of problems and symptoms related to the procedure and the underlying heart disease.These problems include anxiety and depressive symptoms, immobility issues, complications such as wound seeping, neck and shoulder pains, interrupted and insufficient sleep. No studies have tested a combined intervention on phase 1 rehabilitation in coronary artery bypass graft surgery patients. However, randomised trials with either a physical or a mental part have been conducted with positive result, but evidence is lacking for a combined intervention. Before a large randomised trial was set up a pilot trial was conducted to evaluate the feasibility of patient recruitment and intervention: to test the safety and tolerability of the intervention by patients and to provide outcome data for sample size calculations. The SheppHeartCABG pilot showed trial feasibility, safety and sufficient inclusion rate and high compliance with most elements. Outcome data from the pilot trial has been used to sample size and power calculation in this randomised clinical trial.

Objective: The objective of this trial is to investigate the benefits and harms of a phase 1 comprehensive cardiac rehabilitation programme consisting of an exercise-training and a psycho-educative component, including plus treatment as usual in patients who undergo coronary artery bypass grafting.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Daily feedback | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentive, Behavioral: Daily feedback | Intervention Type: BEHAVIORAL; Name: Financial incentive; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Daily feedback; Assigned to Arm(s): Control, Intervention
B: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Exercise-based cardiac rehabilitation program | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise-based cardiac rehabilitation program; Assigned to Arm(s): Experimental group
C: Arm Label: Comprehensive phase one rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Comprehensive phase one rehabilitation | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Comprehensive phase one rehabilitation; Assigned to Arm(s): Comprehensive phase one rehabilitation
D: Arm Label: 12 week exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Structured exercise training | Arm Label: Conventional Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Structured exercise training; Assigned to Arm(s): 12 week exercise training

Answer: C